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Eosinophilic pleural effusion due to
gliclazide
A 52 year-old male ex-smoker was admitted to our hospital
complaining of pleuritic pain in the right chest. The patient
had had normal findings on a previous chest roentgen-
ogram, with no previous pulmonary history or occupa-
tional exposure. He had been suering from diabetes
mellitus type II controlled by diet since 1990. Two weeks
before admission gliclazide was administered. On admis-
sion, a chest X-ray revealed ipsilateral moderate pleural
eusion and small lung infiltrates of the right side,
confirmed by computed tomography scan of the chest.
The leukocyte count was 7500 cellsml71 with 20%
eosinophils, the heamatocrit was 44% and the erythrocyte
sedimentation rate 14 mm for the first hour. A PPD skin
test (Mantoux) with 5 IU PPD was negative. The
dierential cell counts of exudative pleural fluid showed
8% neutrophils, 12% lymphocytes and 80% eosinophils.
Sputum cultures were negative for Mycobacterium tubercu-
losis. Pleural biopsy was negative for tuberculosis or
malignancy. Ova and parasites were not found in the
stools. Fiberoptic bronchoscopy was performed with
normal enodscopic findings. The patient refused transbron-
chial biopsy. Bonchial brushing and washing specimens
were negative for acid-fact bacilii, fungi and malignant
cells. A bronchoalveolar lavage showed 78% macrophages,
10% neutrophils, 10% lymphocytes and 2% eosinophils.
Gliclazide was discontinued and 1 month later the patient
became asymptomatic, eosinophil counts in the blood were
within normal range and the chest roentgenogram showed
complete resolution of the pleural eusion.
Eosinophilic pleural eusions, defined as 10% or more
eosinophils, account for between 5–8% of exudative pleural
eusions (1) and imply a favourable prognosis, based on
their association with benign diagnoses (2). The gliclazide is0954-6111/00/010094+01 $35?00/0an oral sulfonylurea hypoglycaemic agent, which stimulates
insulin secretion by b-cells of the pancreas. Sulfonylouria
compounds such as chlorpropamide (3,4) or tolazamide (5)
have been reported to cause eosinophilic parenchymal lung
disease. However, our patient presented with sub-acute
pleural illness with minimal pulmonary infiltrates.
Although, gliclazide has been reported to cause blood
eosinophilia (unpublished data from pharmaceutical com-
pany’s database), there is no report in the literature of
esinophilic pleural eusion due to sulfonylouria com-
pounds. However, the rapid clinical and roentgenographic
improvement and the return to normal of the blood
eosinophilia after discontinuation of the gliclazide, strongly
suggest a drug-induced disease.
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